Anavex Life Sciences Corp. Class Action Lawsuit - AVXL
Case Summary
Investors who suffered a loss and would like to learn more, click here to contact us.
The Anavex class action lawsuit seeks to represent purchasers or acquirers of Anavex Life Sciences Corp. (NASDAQ: AVXL) publicly traded securities between November 26, 2025 and August 28, 2026, inclusive (the “Class Period”). Captioned Kurey v. Anavex Life Sciences Corp., No. 26-cv-08567 (S.D.N.Y.), the Anavex class action lawsuit charges Anavex and its former CEO with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Anavex class action lawsuit, please provide your information in the form on this page. You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at info@rgrdlaw.com. Lead plaintiff motions for the Anavex class action lawsuit must be filed with the court no later than November 30, 2026.
CASE ALLEGATIONS: Anavex operates as a biopharmaceutical company.
The Anavex class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Anavex lacked adequate internal controls; (ii) Anavex understated its potential regulatory challenges as a result of misconduct by former CEO Christopher Missling; and (iii) as a result, defendants’ statements about Anavex’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
On May 6, 2026, Anavex filed a current report on Form 8-K with the United States Securities and Exchange Commission (“SEC”), allegedly stating that “[o]n April 30, 2026, a special committee (the “Special Committee”) composed of independent directors of the Board of Directors (the “Board”) of Anavex Life Sciences Corp. (the “Company”) terminated the employment of Christopher Missling, PhD as the Company’s Chief Executive Officer for Cause (as defined in the Employment Agreement, dated as of June 27, 2013, between Dr. Missling and the Company, as amended and restated), effective immediately, for, among other things, conduct that the Special Committee believed was inconsistent with Company policy.” On this news, the price of Anavex stock declined nearly 1%, according to the complaint.
On May 11, 2026, after market hours, Anavex filed with the SEC a notification of late filing on Form 12b-25, allegedly stating that Anavex was “unable to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026,” due in part to Anavex’s internal review of “certain matters related to the termination of Dr. Missling.” On this news, the price of Anavex stock fell nearly 6%, according to the complaint.
On August 28, 2026, after market hours, Anavex filed with the SEC an amended annual report on Form 10-K/A for the fiscal year ended September 30, 2025, allegedly disclosing in part that “[a]s a result of the review by the Special Committee, management, in consultation with the Audit Committee of the Board (the “Audit Committee”), concluded that there was a material weakness in internal control over financial reporting that existed at September 30, 2025,” and that Anavex’s “disclosure controls and procedures were not effective as of September 30, 2025, due to the material weakness in internal control over financial reporting as described above.” That same day, Anavex allegedly filed with the SEC its quarterly reports for the periods ending March 31, 2026 and June 30, 2026, which both contained the following disclosure: “[f]ollowing the previously disclosed termination of our former CEO in April 2026, management has determined that our disclosure controls and procedures and our internal controls over financial reporting were not effective as of September 30, 2025, December 31, 2025, March 31, 2026 and June 30, 2026.” On this news, the price of Anavex stock declined more than 6%, according to the complaint.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Anavex publicly traded securities during the Class Period to seek appointment as lead plaintiff in the Anavex class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Anavex class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Anavex class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Anavex class action lawsuit.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig.